相关实验视频

Updated: Jul 12, 2025

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

在体外和体外拯救一个无意义的突变,负责严重的凝血因子V缺乏症

Alice M Todaro¹, Claudia M Radu², Maria Ciccone³

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.

Journal of thrombosis and haemostasis : JTH

|October 22, 2023

概括

像G418和2,6-DAP这样的读透剂在治疗由F5 p.Arg1161Ter突变引起的V因子 (FV) 缺乏症方面表现有前途. 这些药物可以在体外和体外恢复功能性FV水平,为这种罕见的出血障碍提供潜在的新疗法.

科学领域:

血液学血液学血液学
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

凝血因子V (FV) 缺乏症是一种罕见的出血障碍.
目前的管理依赖于新鲜冷的血输血.
在FV的无意义突变可能可以用读透剂治疗.

研究的目的:

评估F5 p.Arg1161Ter突变的阅读疗法的疗效.
研究特定的读透剂在治疗FV缺陷方面的潜力.

主要方法:

在患有F5 p.Arg1161Ter突变的患者中评估F5mRNA和蛋白质.
在体外和体外模型中测试了五种读透剂 (G418,ELX-02,PTC-124,2,6-DAP,Amlexanox).
利用细胞培养,血栓生成试验和巨核细胞分化.

主要成果:

患者表现出F5 p.Arg1161Ter突变的自然读透.
在体外,G418,ELX-02和2,6-DAP剂量依赖性增加了FV活性.
活体外,读透剂恢复了患者衍生的巨核细胞中的FV表达,使功能FV的吸收成为可能.

结论:

在体外和体外证明了针对F5 p.Arg1161Ter突变的阅读疗法的原理证明.
确定G418和2,6-DAP是进一步调查的有希望的候选人.
阅读疗法为这种特定的FV缺陷提供了潜在的新型治疗策略.

关键词:

发生出血,出血.这是V因子缺乏症.巨核细胞是巨核细胞.没有意义的突变突变.没有意义的媒介衰变.翻译阅读通过翻译.

更多相关视频

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

相关概念视频

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.